{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:55:10Z","timestamp":1781754910913,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100008235","name":"Peking Union Medical College Hospital","doi-asserted-by":"publisher","award":["UHB11983"],"award-info":[{"award-number":["UHB11983"]}],"id":[{"id":"10.13039\/501100008235","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573978"],"award-info":[{"award-number":["82573978"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012232","name":"National Key Clinical Specialty Discipline Construction Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7242109"],"award-info":[{"award-number":["7242109"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13555-026-01787-x","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T16:43:44Z","timestamp":1779122624000},"page":"3431-3443","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase\u00a0I\/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial"],"prefix":"10.1007","volume":"16","author":[{"given":"Chao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuping","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengguang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunhuo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuetong","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjia","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6234-1554","authenticated-orcid":false,"given":"Hongzhong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"3","key":"1787_CR1","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jaad.2020.07.025","volume":"84","author":"S Elmariah","year":"2021","unstructured":"Elmariah S, Kim B, Berger T, et al. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. J Am Acad Dermatol. 2021;84(3):747\u201360. https:\/\/doi.org\/10.1016\/j.jaad.2020.07.025.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"1787_CR2","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/jdv.14570","volume":"32","author":"MP Pereira","year":"2018","unstructured":"Pereira MP, Steinke S, Zeidler C, et al. European Academy of Dermatology and Venereology European Prurigo Project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol. 2018;32(7):1059\u201365. https:\/\/doi.org\/10.1111\/jdv.14570.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1787_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/17512433.2021.1852080","volume":"14","author":"KA Williams","year":"2021","unstructured":"Williams KA, Roh YS, Brown I, et al. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis. Expert Rev Clin Pharmacol. 2021;14(1):67\u201377. https:\/\/doi.org\/10.1080\/17512433.2021.1852080.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"1787_CR4","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jid.2019.07.697","volume":"140","author":"AH Huang","year":"2020","unstructured":"Huang AH, Canner JK, Khanna R, Kang S, Kwatra SG. Real-world prevalence of prurigo nodularis and burden of associated diseases. J Invest Dermatol. 2020;140(2):480-3.e4. https:\/\/doi.org\/10.1016\/j.jid.2019.07.697.","journal-title":"J Invest Dermatol"},{"issue":"22","key":"1787_CR5","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1097\/cm9.0000000000003732","volume":"138","author":"L Zhang","year":"2025","unstructured":"Zhang L, Diao Q, Dou X, et al. Guidelines for the diagnosis and treatment of prurigo nodularis. Chin Med J (Engl). 2025;138(22):2859\u201361. https:\/\/doi.org\/10.1097\/cm9.0000000000003732.","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"1787_CR6","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.jaad.2018.09.020","volume":"80","author":"AA Qureshi","year":"2019","unstructured":"Qureshi AA, Abate LE, Yosipovitch G, Friedman AJ. A systematic review of evidence-based treatments for prurigo nodularis. J Am Acad Dermatol. 2019;80(3):756\u201364. https:\/\/doi.org\/10.1016\/j.jaad.2018.09.020.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1787_CR7","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1001\/archderm.134.12.1532","volume":"134","author":"MD Njoo","year":"1998","unstructured":"Njoo MD, Spuls PI, Bos JD, Westerhof W, Bossuyt PM. Nonsurgical repigmentation therapies in vitiligo: meta-analysis of the literature. Arch Dermatol. 1998;134(12):1532\u201340. https:\/\/doi.org\/10.1001\/archderm.134.12.1532.","journal-title":"Arch Dermatol"},{"issue":"8","key":"1787_CR8","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/jamadermatol.2019.0696","volume":"155","author":"JH Lee","year":"2019","unstructured":"Lee JH, Kwon HS, Jung HM, et al. Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis. JAMA Dermatol. 2019;155(8):929\u201338. https:\/\/doi.org\/10.1001\/jamadermatol.2019.0696.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1787_CR9","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.jaad.2020.04.183","volume":"83","author":"AH Huang","year":"2020","unstructured":"Huang AH, Williams KA, Kwatra SG. Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol. 2020;83(6):1559\u201365. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.183.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1787_CR10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","volume":"77","author":"S Banerjee","year":"2017","unstructured":"Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77(5):521\u201346. https:\/\/doi.org\/10.1007\/s40265-017-0701-9.","journal-title":"Drugs"},{"issue":"1","key":"1787_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/ejp.767","volume":"20","author":"C Zeidler","year":"2016","unstructured":"Zeidler C, St\u00e4nder S. The pathogenesis of prurigo nodularis\u2013\u2018super-itch\u2019 in exploration. Eur J Pain. 2016;20(1):37\u201340. https:\/\/doi.org\/10.1002\/ejp.767.","journal-title":"Eur J Pain"},{"issue":"6","key":"1787_CR12","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jaad.2020.04.182","volume":"83","author":"KA Williams","year":"2020","unstructured":"Williams KA, Huang AH, Belzberg M, Kwatra SG. Prurigo nodularis: pathogenesis and management. J Am Acad Dermatol. 2020;83(6):1567\u201375. https:\/\/doi.org\/10.1016\/j.jaad.2020.04.182.","journal-title":"J Am Acad Dermatol"},{"key":"1787_CR13","doi-asserted-by":"publisher","DOI":"10.25259\/ijdvl_362_2023","author":"K Sardana","year":"2023","unstructured":"Sardana K, Rose Mathachan S, Agrawal D. Treatment of recalcitrant paediatric prurigo nodularis with tofacitinib, an exquisite example of bench-to-bedside translation of JAK-STAT expression. Indian J Dermatol Venereol Leprol. 2023. https:\/\/doi.org\/10.25259\/ijdvl_362_2023.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"9","key":"1787_CR14","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.1111\/jocd.14709","volume":"21","author":"D Agrawal","year":"2022","unstructured":"Agrawal D, Sardana K, Mathachan SR, Bhardwaj M, Ahuja A, Jain S. A prospective study examining the expression of STAT 1, 3, 6 in prurigo nodularis lesions with its immunopathogenic and therapeutic implications. J Cosmet Dermatol. 2022;21(9):4009\u201315. https:\/\/doi.org\/10.1111\/jocd.14709.","journal-title":"J Cosmet Dermatol"},{"key":"1787_CR15","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","volume":"10","author":"MD Howell","year":"2019","unstructured":"Howell MD, Kuo FI, Smith PA. Targeting the janus kinase family in autoimmune skin diseases. Front Immunol. 2019;10:2342. https:\/\/doi.org\/10.3389\/fimmu.2019.02342.","journal-title":"Front Immunol"},{"issue":"2","key":"1787_CR16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40257-018-0413-2","volume":"20","author":"H He","year":"2019","unstructured":"He H, Guttman-Yassky E. JAK inhibitors for atopic dermatitis: an update. Am J Clin Dermatol. 2019;20(2):181\u201392. https:\/\/doi.org\/10.1007\/s40257-018-0413-2.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1787_CR17","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.jaci.2022.03.010","volume":"149","author":"M Steinhoff","year":"2022","unstructured":"Steinhoff M, Ahmad F, Pandey A, et al. Neuroimmune communication regulating pruritus in atopic dermatitis. J Allergy Clin Immunol. 2022;149(6):1875\u201398. https:\/\/doi.org\/10.1016\/j.jaci.2022.03.010.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"1787_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","volume":"171","author":"LK Oetjen","year":"2017","unstructured":"Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217-28.e13. https:\/\/doi.org\/10.1016\/j.cell.2017.08.006.","journal-title":"Cell"},{"issue":"7","key":"1787_CR19","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/ced.14320","volume":"45","author":"OE Molloy","year":"2020","unstructured":"Molloy OE, Kearney N, Byrne N, Kirby B. Successful treatment of recalcitrant nodular prurigo with tofacitinib. Clin Exp Dermatol. 2020;45(7):918\u201320. https:\/\/doi.org\/10.1111\/ced.14320.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"1787_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.8606","volume":"12","author":"F Sun","year":"2024","unstructured":"Sun F, Wu Z. Successful treatment of refractory prurigo nodularis with abrocitinib. Clin Case Rep. 2024;12(3):e8606. https:\/\/doi.org\/10.1002\/ccr3.8606.","journal-title":"Clin Case Rep"},{"key":"1787_CR21","unstructured":"St\u00e4nder S, Tyring S, Fleischer A, et al. Efficacy and safety of ruxolitinib cream in patients with prurigo nodularis: pooled results from the phase 3 TRuE-PN1 and TRuE-PN2 randomized, vehicle-controlled studies. European Academy of Dermatology and Venereology Congress; September 17\u201320; Paris, France; 2025. p. LBA-281."},{"issue":"4","key":"1787_CR22","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","volume":"85","author":"K Papp","year":"2021","unstructured":"Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2021.04.085.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1787_CR23","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.anai.2022.12.033","volume":"130","author":"DYM Leung","year":"2023","unstructured":"Leung DYM, Paller AS, Zaenglein AL, et al. Safety, pharmacokinetics, and efficacy of ruxolitinib cream in children and adolescents with atopic dermatitis. Ann Allergy Asthma Immunol. 2023;130(4):500-7.e3. https:\/\/doi.org\/10.1016\/j.anai.2022.12.033.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"1787_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","volume":"12","author":"DM Schwartz","year":"2016","unstructured":"Schwartz DM, Bonelli M, Gadina M, O\u2019Shea JJ. Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25\u201336. https:\/\/doi.org\/10.1038\/nrrheum.2015.167.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"1787_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jaci.2007.04.031","volume":"120","author":"MD Howell","year":"2007","unstructured":"Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2007;120(1):150\u20135. https:\/\/doi.org\/10.1016\/j.jaci.2007.04.031.","journal-title":"J Allergy Clin Immunol"},{"issue":"20","key":"1787_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012390","volume":"23","author":"LS Wong","year":"2022","unstructured":"Wong LS, Yen YT. Chronic nodular prurigo: an update on the pathogenesis and treatment. Int J Mol Sci. 2022;23(20):12390. https:\/\/doi.org\/10.3390\/ijms232012390.","journal-title":"Int J Mol Sci"},{"key":"1787_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119889","volume":"590","author":"I Persaud","year":"2020","unstructured":"Persaud I, Diamond S, Pan R, et al. Plasma pharmacokinetics and distribution of ruxolitinib into skin following oral and topical administration in minipigs. Int J Pharm. 2020;590:119889. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119889.","journal-title":"Int J Pharm"},{"issue":"15","key":"1787_CR28","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2010","unstructured":"Quint\u00e1s-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109\u201317. https:\/\/doi.org\/10.1182\/blood-2009-04-214957.","journal-title":"Blood"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01787-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01787-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01787-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:24:10Z","timestamp":1781753050000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01787-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1787"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01787-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"10 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Chao Wu, Xuping Niu, Xiaohua Wang, Juan Su, Hengguang Zhao, Mao Lin, Chunjun Yang, Xiaoming Qin, Shuping Guo, Cunhuo Jiang, Hui Tang, Haijing Yang, Liming Wu, Min Zhu, Aihua Wei, Xiaohua Tao, Yiwen Zhang, Chang Shu, Jiawei Liu, Lu Yang, Yuetong Qian, Bingjie Zhang, Shiyu Zhang, Junfang Xu, Yang Lu, Mingjia Peng, Shizheng Luo, Weijie Ma, and Hongzhong Jin have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was approved by the Ethics Committee (EC) for Clinical Trials of Drugs at the lead site, Peking Union Medical College Hospital (Approval number KS20241626), and by the ECs of all participating sites (full list in Online Resource Table\u00a0\n                      \n                      ). Written informed consent was obtained from all participants prior to study procedures. The participants consented to the submission of the case details and images to the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}